Annual report

VALBIOTIS publishes its 2018 annual report and announces its results.

Read the document

VALEDIA®

VALBIOTIS obtains the European patent for VALEDIA®.

Read the press release

VALEDIA®

A major scientific innovation for people with prediabetes.

Prediabetes

VALBIOTIS publishes the first prediabetes market data.

Read the press release

1 4

S c r o l l

Products

.01

Pipeline

4 products in clinical development

.02

VALEDIA® – Prediabetes

Prediabetes
• Reduction of the risk of type 2 diabetes
• Phase IIa clinical study ongoing

.03

LpD64

Overweight and /or obesity
• Modulation of intestinal microbiota
• Clinical Phase I/II positive

.04

VAL-070

Mild to moderate hypercholesterolemia
• Reduction of blood LDL-cholesterol
• Clinical Phase I/II positive

.05

VALEDIA® – Non alcoholic fatty liver

Non-alcoholic fatty liver (NAFL)
• Reduction of NAFL, risk factor for NASH
• Clinical Phase I/II positive

Key figures

Patent families filed

4

All exploitation rights obtained

Employees

> 35

75% in R&D

Listed on the Stock Exchange

2017

Euronext Growth

Our last posts

15.03.2019

Les Echos : Maladie de civilisation recherche prévention efficiente

En savoir plus

05.02.2019

Biotech Day, SFAF, Paris

En savoir plus

22.01.2019

Biomed Event, Invest Securities, Paris

En savoir plus

07.01.2019

J.P. Morgan Healthcare Conference

En savoir plus

Voir tous

VALBIOTIS© listed on the Stock Exchange

Investors

Follow us!